ANTENGENE-B (06996) Shareholders Deposit Shares into Standard Chartered Bank (Hong Kong) with Market Value of HK$416 Million

Stock News

Aug 19

According to the latest data from the Hong Kong Stock Exchange, on August 18, shareholders of ANTENGENE-B (06996) deposited shares into Standard Chartered Bank (Hong Kong), with a deposited market value of HK$416 million, representing 9.23% of the company's shares. On July 28, ANTENGENE announced that China's National Medical Products Administration (NMPA) has approved Selinexor (in combination with bortezomib and dexamethasone (XVd)) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. This represents a new indication for Selinexor.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1110197995"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110197995\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110197995?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 08:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110197995","market":"us","top_or_hot":-1,"title":"ANTENGENE-B (06996) Shareholders Deposit Shares into Standard Chartered Bank (Hong Kong) with Market Value of HK$416 Million","media":"Stock News","content":"<p>According to the latest data from the Hong Kong Stock Exchange, on August 18, shareholders of ANTENGENE-B (06996) deposited shares into Standard Chartered Bank (Hong Kong), with a deposited market value of HK$416 million, representing 9.23% of the company's shares. On July 28, ANTENGENE announced that China's National Medical Products Administration (NMPA) has approved Selinexor (in combination with bortezomib and dexamethasone (XVd)) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. This represents a new indication for Selinexor.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ANTENGENE-B (06996) Shareholders Deposit Shares into Standard Chartered Bank (Hong Kong) with Market Value of HK$416 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nANTENGENE-B (06996) Shareholders Deposit Shares into Standard Chartered Bank (Hong Kong) with Market Value of HK$416 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-19 08:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to the latest data from the Hong Kong Stock Exchange, on August 18, shareholders of ANTENGENE-B (06996) deposited shares into Standard Chartered Bank (Hong Kong), with a deposited market value of HK$416 million, representing 9.23% of the company's shares. On July 28, ANTENGENE announced that China's National Medical Products Administration (NMPA) has approved Selinexor (in combination with bortezomib and dexamethasone (XVd)) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. This represents a new indication for Selinexor.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06996","symbol_name":"德琪医药-B","start_time":0,"source_url":"","article_id":"1110197995","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110197995","pubTimestamp":1755563787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to the latest data from the Hong Kong Stock Exchange, on August 18, shareholders of ANTENGENE-B (06996) deposited shares into Standard Chartered Bank (Hong Kong), with a deposited market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06996":"德琪医药-B","BK1191":"制药","BK1583":"高瓴概念","BK1574":"生物医药B类股"},"translate_title":"德琪-B(06996)股东入股渣打银行（香港）市值4.16亿港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":1},"content_text":"According to the latest data from the Hong Kong Stock Exchange, on August 18, shareholders of ANTENGENE-B (06996) deposited shares into Standard Chartered Bank (Hong Kong), with a deposited market value of HK$416 million, representing 9.23% of the company's shares. On July 28, ANTENGENE announced that China's National Medical Products Administration (NMPA) has approved Selinexor (in combination with bortezomib and dexamethasone (XVd)) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. This represents a new indication for Selinexor.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}